Autologous lymphapheresis for the production of chimeric antigen receptor T cells
Transfusion2017Vol. 57(5), pp. 1133–1141
Citations Over TimeTop 10% of 2017 papers
Elizabeth S. Allen, David F. Stroncek, Jiaqiang Ren, Anne F. Eder, Kamille A. West, Terry J. Fry, Daniel W. Lee, Crystal L. Mackall, Cathy Conry‐Cantilena
Abstract
In most patients undergoing CAR T-cell therapy, leukapheresis is well tolerated, and adequate numbers of CD3+ lymphocytes are collected.
Related Papers
- → Risks of leukapheresis and how to manage them—A non-systematic review(2018)22 cited
- → Peripheral blood progenitor cell collection in pediatric patients optimized by high pre-apheresis count of circulating CD34+ cells and high blood flow(2018)10 cited
- → Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy(2005)9 cited
- → Circulating CD34+ cell counts as predictive parameter for the efficacy of peripheral stem cell apheresis in Ewing Tumor patients(1997)13 cited
- → Apheresis: An Overview of Procedures and Need for Vascular Access Devices(2004)2 cited